Can bone loss in rheumatoid arthritis be prevented?

• Published in: Osteoporosis international 2013-10, Vol.24 (10), p.2541-2553
• Main Authors: Vis, M., Güler-Yüksel, M., Lems, W. F.
• Format: Article
• Language: English
• Subjects: Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - drug therapy; Biological products; Biological Products - therapeutic use; Cross-Sectional Studies; Drug Therapy, Combination; Endocrinology; Glucocorticoids - therapeutic use; Humans; Medicine; Medicine & Public Health; Orthopedics; Osteoporosis; Osteoporosis - diagnosis; Osteoporosis - etiology; Osteoporosis - prevention & control; Preventive medicine; Review; Rheumatoid arthritis; Rheumatology; Risk Factors
• ISSN: 0937-941X; 1433-2965
• DOI: 10.1007/s00198-013-2334-5

Rheumatoid arthritis (RA) is a systemic inflammatory disease that can lead to local joint deformations (bone erosions and joint space narrowing) and to extra-articular phenomena, including generalized osteoporosis. In addition, in patients with RA, the risk of vertebral and nonvertebral fractures is doubled. High disease activity (inflammation), immobility, and glucocorticoid use are common factors that substantially increase fracture risk in these patients, on top of the background fracture risk based on classical risk factors such as high age, low body mass, and female gender. New insights on the links between the immune system and the bone system, the field of osteoimmunology, have shown that local and generalized bone loss share common pathways. The receptor activator of nuclear factor κB ligand/osteoprotegerin pathway (RANKl/OPG) is one of the most important pathways, as it is (strongly) upregulated by inflammation. In modern treatment of RA with biologics, for example, TNFα-blocking agents and combination therapy of conventional disease-modifying antirheumatic drugs (DMARDs), clinical remission is a realistic treatment goal. As a consequence, in recent studies, it has been documented that both local and generalized bone loss is absent or minimal in those patients who are in clinical remission.